Aim: To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians and evaluate treatment trends and baseline concordance versus guidelines internationally.
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
